Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser.

Journal: Journal Of AAPOS : The Official Publication Of The American Association For Pediatric Ophthalmology And Strabismus
Published:
Abstract

An infant of 36 weeks' postmenstrual age (PMA) and 25 weeks' gestation received bilateral intravitreal bevacizumab injections for type 1 retinopathy of prematurity. He underwent laser photocoagulation in both eyes 5 days later, confluent except for 1 clock hour obscured by hemorrhage in the left eye. Despite initial regression, neovascularization in both vascularized and lasered retina with plus disease recurred, requiring repeat laser bilaterally at 51 weeks' PMA and vitrectomy in the left eye at 54 weeks' PMA. Whereas late recurrence is thought to occur rarely after laser treatment, infants who have received both bevacizumab injections and laser may still require long-term surveillance for recurrence. In this case, fundus photography proved valuable for appreciating recurrent plus disease because the initial treatments had resulted in marked retinal vessel attenuation.

Authors
Wendy Chen, Gil Binenbaum, Karen Karp, Agnieshka Baumritter, Denise Pearson, Albert Maguire, Graham Quinn
Relevant Conditions

Retinopathy of Prematurity